Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The …
Over the last 12 months, insiders at Bausch Health Companies Inc. have bought $0 and sold $146,846 worth of Bausch Health Companies Inc. stock.
On average, over the past 5 years, insiders at Bausch Health Companies Inc. have bought $68.53M and sold $10.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $1.45M was made by Miller Steven D (director) on 2021‑11‑30.
2024-09-06 | Sale | EVP, General Counsel | 13,370 0.0036% | $6.21 | $83,028 | +31.40% | ||
2024-03-04 | Sale | EVP, General Counsel | 6,313 0.0018% | $9.80 | $61,867 | -20.67% | ||
2023-12-05 | Sale | EVP, General Counsel | 220 <0.0001% | $7.38 | $1,624 | +12.36% | ||
2023-11-06 | Sale | EVP, General Counsel | 43 <0.0001% | $7.61 | $327 | +4.83% | ||
2023-09-06 | Sale | EVP, General Counsel | 6,685 0.0018% | $8.28 | $55,352 | -8.67% | ||
2023-03-06 | Sale | EVP, General Counsel | 495 0.0001% | $9.17 | $4,539 | -10.20% | ||
2023-03-03 | Sale | EVP, General Counsel | 780 0.0002% | $9.34 | $7,285 | -14.30% | ||
2023-02-28 | Sale | EVP, General Counsel | 292 <0.0001% | $9.32 | $2,721 | -15.31% | ||
2022-04-14 | Sale | U.S. President-Pharma Business | 1,595 0.0004% | $22.19 | $35,393 | -65.94% | ||
2022-03-15 | Sale | U.S. President-Pharma Business | 4,846 0.0014% | $22.20 | $107,581 | -65.00% | ||
2022-03-08 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 3,889 0.0011% | $21.76 | $84,625 | -64.35% | ||
2022-03-02 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 11,077 0.003% | $23.37 | $258,869 | -68.14% | ||
2022-03-02 | Sale | U.S. President-Pharma Business | 1,595 0.0004% | $23.37 | $37,275 | -68.14% | ||
2022-03-01 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 6,338 0.0018% | $23.82 | $150,971 | -67.14% | ||
2022-02-15 | Sale | U.S. President-Pharma Business | 3,251 0.0009% | $25.02 | $81,340 | -69.84% | ||
2022-01-18 | Sale | U.S. President-Pharma Business | 3,251 0.0009% | $26.63 | $86,574 | -70.45% | ||
2021-11-30 | director | 60,000 0.017% | $24.23 | $1.45M | -60.82% | |||
2021-08-05 | director | 2,800 0.0008% | $25.94 | $72,632 | -6.04% | |||
2021-08-04 | director | 20,000 0.0056% | $25.01 | $500,246 | -2.62% | |||
2021-06-11 | Sale | EVP & Chief Financial Officer | 34,000 0.0094% | $31.68 | $1.08M | -17.77% |
Paulson John | 25839035 7.0386% | $9.54 | 5 | 2 | +31.4% | |
ValueAct Holdings, L.P. | director | 17931594 4.8846% | $9.54 | 19 | 3 | +19.98% |
Pearson J. Michael | Chief Executive Officer | 1514664 0.4126% | $9.54 | 2 | 1 | +21.28% |
Morfit G Mason | See Remarks | 1352941 0.3685% | $9.54 | 1 | 0 | +30.3% |
UBBEN JEFFREY W | director | 1059793 0.2887% | $9.54 | 3 | 1 | +44.4% |
ICAHN CARL C | $368.39M | 9.62 | 34.72M | 0% | +$0 | 3.29 | |
GoldenTree Asset Management | $293.31M | 7.66 | 27.64M | 0% | +$0 | 25.67 | |
Paulson & Co. | $280.52M | 7.32 | 26.44M | 0% | +$0 | 19.38 | |
Franklin Templeton Investments | $168.18M | 4.39 | 15.85M | +0.32% | +$528,788.17 | 0.05 | |
National Bank Of Canada Fi | $107.75M | 4.34 | 15.66M | +0.07% | +$80,874.83 | 0.18 |